These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 17935283)

  • 1. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M
    J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth factor receptors: implications in tumor biology.
    Srinivasan DM; Kapoor M; Kojima F; Crofford LJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1246-9. PubMed ID: 16370390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors.
    Hamadeh HK; Todd M; Healy L; Meyer JT; Kwok AM; Higgins M; Afshari CA
    Chem Res Toxicol; 2010 Jun; 23(6):1025-33. PubMed ID: 20521778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
    Renhowe PA
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combinations based on epidermal growth factor receptor inhibition.
    Adjei AA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
    Nurmio M; Kallio J; Toppari J; Jahnukainen K
    Reprod Toxicol; 2008 Aug; 25(4):442-6. PubMed ID: 18472395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B; Bran G; Hörmann K; Riedel F
    Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging targeted therapies for breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.